TRV GP Iv, LLC

In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 13, 2026), TRV GP Iv, LLC reported 2 stock positions worth $255.1 million. Its top holding was Maze Therapeutics (MAZE) at 72.7% of the portfolio, followed by Tango Therapeutics (TNGX, 27.3%). Compared with Q3 2025, it reduced 2. The biggest sale was Tango Therapeutics (TNGX, shares −43%).

Most Recent 13F
Q2 2026
Location
Boston, MA
CIK
0001688325
Portfolio Value
$255.1M (Q4 2025)
SEC Filing
0001193125-26-051795 ↗ filed Feb 13, 2026

Holdings Value

0$100.0M$200.0M$300.0M Q1 2024: $206.4M Q1 2024 Q2 2024: $202.2M Q2 2024 Q3 2024: $162.1M Q3 2024 Q4 2024: $80.2M Q4 2024 Q1 2025: $92.9M Q1 2025 Q2 2025: $163.3M Q2 2025 Q3 2025: $274.0M Q3 2025 Q4 2025: $255.1M $255.1M Q4 2025 Q1 2026: $266.9M Q1 2026 Q2 2026: $253.7M Q2 2026

Holdings 2 stocks · $255.1M
MAZE Maze Therapeutics Inc. 72.65% 4,473,958 $185.4M Reduce -26.3%
TNGX Tango Therapeutics Inc. 27.35% 7,874,574 $69.8M Reduce -43.2%

Portfolio Sells Q3 2025 → Q4 2025
TNGX Tango Therapeutics Inc. Reduce -43.2% 27.35% −15.16
MAZE Maze Therapeutics Inc. Reduce -26.3% 72.65% +15.16

Portfolio Buys Q3 2025 → Q4 2025
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 2$253.7MMAZE, TNGX
Q1 2026 2$266.9MMAZE, TNGX
Q4 2025 2$255.1MMAZE, TNGX
Q3 2025 2$274.0MMAZE, TNGX
Q2 2025 3$163.3MTNGX, MAZE, PLRX
Q1 2025 3$92.9MMAZE, TNGX, PLRX
Q4 2024 2$80.2MTNGX, PLRX
Q3 2024 3$162.1MTNGX, PLRX, FULC
Q2 2024 3$202.2MTNGX, PLRX, FULC
Q1 2024 3$206.4MTNGX, PLRX, FULC